
ERRATUM**Current and emerging therapeutic targets for IBD***Markus Neurath**Nature Reviews Gastroenterology & Hepatology* **14**, 269–278 (2017)

In the version of this Review published online and in print, representation of the target for the drugs ustekinumab, risankizumab and MEDI2070 were not accurate in Figure 3 and should have highlighted that ustekinumab targets IL-12 and IL-23, whereas MEDI2070 and risankizumab both act on IL-23. The error has been corrected for the HTML and PDF versions of the article.